MILESTONE PHARMACEUTICALS

Milestone Pharmaceuticals’ stock rose after the company reported that the first patient was enrolled in the phase‑3 ReVeRA‑301 study to treat atrial fibrillation with rapid ventricular response (AFib‑RVR). ReVeRA‑301 is multicenter, randomized, double‑blind and placebo‑controlled and is expected to enroll about 150 patients; the primary endpoint is reduction of ventricular rate within 30 minutes. The trial is testing a repeatedly administered 70‑mg etripamil nasal spray, which is already approved for PSVT as CARDAMYST, with the goal of an sNDA approval pathway based on this study. Patients are intended to self‑administer the treatment in medically unsupervised settings such as at home. » More on de.investing.com

Milestone Pharmaceuticals reported a net loss of $0.16 per share for Q4 2025, meeting analyst expectations. The company recorded revenue for the first time—$1.5 million—from a licensing collaboration following FDA approval of CARDAMYST. Despite the product launch, the stock fell 4.7% in premarket trading, weighed down by higher operating expenses and ongoing net losses. Milestone forecasts cash runway through the end of 2027 and is focusing on the launch of CARDAMYST and the European approval strategy for TACHYMIST. » More on de.investing.com

Milestone Pharmaceuticals will publish results for the quarter ended 31 Dec 2025 on 20 Mar 2026. Five analysts on average expect a loss per share of -0.160 USD (prior year: -0.190 USD) and revenue of 0.0 million USD. For the past fiscal year, five analysts on average forecast a loss per share of -0.716 USD with revenue of 0.0 million USD. » More on finanzen.net